Global X Telemedicine & Digital Health ETF

Market Expects HIMS Profit to Surge 174%, Stock Price Rises 30% in a Month

Hims & Hers Health Suffers Data Breach via Third-Party Platform, Exposing Sensitive Customer Information

Tempus AI's 2026 EPS Estimate Median Revised Down to -0.51

Hims & Hers Health suggested to be potentially transforming into an AI company

Hims & Hers Health's Latest Moves: Targeting the $200B Weight-Loss Market and Addressing a Hacker Incident

ResMed CEO Michael Farrell Sells Company Stock

Tempus AI Expands Collaboration with Gilead Sciences to Advance Oncology R&D Pipeline

Amazon Pharmacy to offer Lilly's GLP-1 pill, Hims & Hers stock falls on increased competition

Tempus AI to Present at the 25th Annual Needham Virtual Healthcare Conference

Citigroup Analyst Maintains Buy Rating on ResMed

Goldman Sachs Analyst Maintains Buy Rating on Insulet

Goldman Sachs analyst maintains hold rating on Irhythm Technologies

Citi Sees ResMed Q3 FY2026 Revenue at $1.44B but Margins Cut

Tempus AI announced ALERT trial results, showing its AI-driven alerts improved cardiac care.

Hims & Hers CEO Targets 100,000 Monthly Wegovy Prescriptions, Stock Jumps in Premarket Trading

Bank of America lowers Hims & Hers price target to $21, citing EBITDA concerns

Hims & Hers Health (HIMS) Is Down 6.1% After Expanding GLP-1 Access With Novo Nordisk Collaboration

Seeking Alpha Quant Rating designates Hims & Hers Health as "Strong Sell"

Aberdeen Group plc Discloses Increased Stake in Tempus AI

Hims & Hers Health Restarts Collaboration with Novo Nordisk, Offering GLP-1 Drugs Again

Fusemachines

Erayak Power Solution

Smart Powerr

Sky Quarry

Cue BioPharma

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

ZeZentalis Pharma

XCF Global

Rackspace Tech

U Power

TSLQ

FDHT

EDOC

TDOC

HEAL

Wall Street saw gains with the S&P 500 up 3.3% this week. Oracle plans to cut 20,000-30,000 jobs to boost cash flow amid AI investments. Tesla delivered 358,023 vehicles, missing estimates, while Nike's guidance disappointed, forecasting a sales decline. Applied Optoelectronics surged 20% after a $71 million order, and Teladoc Health rose 6% amid activist investor pressure for a buyback and strategic review.

- Wall Street closed the trading week on a positive note, driven by a robust March jobs report.  
- The Nasdaq Composite increased by 4.4%, the S&P 500 rose by 3.3%, and the Dow climbed by 2.9%.  
- Geopolitical tensions contributed to rising oil prices, while Oracle is reportedly reducing its workforce significantly.

SPDR S&P 500

AXS TSLA Bear Daily ETF

iShares Core S&P 500

Applied Optoelectronics

T-Rex 2X Long Tesla Daily Target ETF

Fidelity Digital Health ETF

iShares MSCI USA Min Vol Factor ETF

Direxion Daily TSLA Bear 1X Shares

SPDR FD Consumer Discretionary

Ps S&P Low Vol

SPDR S&P Retail ETF

VanEck Retail ETF

Invesco S&P 500 Eq Wgt ETF

VG S&P 500

Global X Cloud Computing ETF

GraniteShares 1.25 Long TSLA Daily ETF

Teladoc

Invesco Nasdaq Future Gen 200 ETF

GraniteShares 2x Long TSLA Daily ETF

Nike

Defiance Daily Target 2X Long ORCL ETF

Global X HealthTech ETF

Oracle

GraniteShares 2x Short TSLA Daily ETF

Simplify Volt TSLA Revolution ETF

T-Rex 2X Inverse Tesla Daily Target ETF

Global X Nasdaq 100 Covered Call ETF

Leverage Shares 2X Long TSLA Daily ETF

S&P 500

Direxion Daily TSLA Bull 2X Shares

ISHRS S&P Glb It

Tesla

Trending stocks this week as S&P 500 notches best weekly gain in 5 months

Pineal Capital Management is urging Teladoc Health Inc. to enhance shareholder value through buybacks, cost reductions, and a strategic review, citing concerns over its low valuation and potential takeover risks. The firm criticized past acquisitions and the lack of buybacks, noting Teladoc's stock has dropped over 90% since pre-COVID highs. Pineal proposed a three-part strategy to improve performance, highlighting strong fundamentals and growth potential in Teladoc's mental health segment. Despite recent quarterly results exceeding expectations, Teladoc's shares were down 0.64% at $5.52 at the time of publication.

benzinga_article

Teladoc Faces Pressure Over Capital Allocation And Stock Underperformance

SHLT

SHL Telemedicine Narrows Loss and Bolsters Balance Sheet as Turnaround Advances

Tip Ranks

SHL TeleMedicine

SHL Telemedicine Narrows Loss and Bolsters Balance Sheet as Turnaround Advances

Teladoc Adds Susan Salka to Expanded Board of Directors

Teladoc Adds Susan Salka to Expanded Board of Directors

UberDoc Health Technologies Corp., a digital healthcare marketplace, has gone public on the Canadian Securities Exchange following a successful reverse merger. Founded by Dr. Paula Muto and led by CEO Sean Kearney, UberDoc connects patients with board-certified specialists, emphasizing transparent pricing. The company received a 2026 Dealmakers Award for this achievement, which positions it for growth in the healthcare sector. With operations in Vancouver and Boston, UberDoc aims to enhance patient access to care while providing physicians with greater control over their practices.

UberDoc Honored for Reverse Merger as Healthcare Marketplace Goes Public on CSE

Welldoc® has been awarded the 2026 Artificial Intelligence Excellence Award by the Business Intelligence Group, marking its third consecutive win in the Health Product category. This recognition highlights Welldoc's leadership in healthcare-ready AI, which combines clinical precision with regulated capabilities to provide personalized insights for individuals and healthcare organizations. The company aims to enhance health outcomes through innovative, evidence-based support programs and has been acknowledged as an early adopter in the CMS Health Tech Ecosystem Initiative.

MorningStar

Welldoc® Honored with 2026 Artificial Intelligence Excellence Award

159898

SBIO

562600

159883

JM Financial has maintained a ‘Buy’ rating on Global Health Ltd, operator of Medanta Hospitals, raising the target price to Rs 1,382, a 42% increase. The firm cites improving earnings visibility and margin expansion, despite a 30% stock correction over six months due to concerns about the Noida unit and geopolitical tensions. Medanta's limited exposure to Middle East patients and strong performance at its Gurugram facility support growth. The company plans to expand capacity significantly by FY29, with expected revenue and profit growth rates of 14% and 32%, respectively, over FY26–FY28.

Money Control

SPDR S&P Health Equip

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ALPS Medical Breakthrough

SPDR S&P Health

ChinaAMC CSI All Share Health Care Devices ETF

iShares US Healthcare Providers

iShares US Medical Devices

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

JM Financial maintains ‘Buy’ on Medanta; sets target price higher by 42% at Rs 1,382

Analysts at JM Financial maintain a ‘Buy’ rating on Global Health (Medanta), citing a 42% upside potential following a recent stock correction. Medanta's stock has dropped 30% over six months, attributed to the Noida unit launch and geopolitical concerns. The analysts project strong growth, with a target price of ₹1,382, reflecting a 42.47% upside from the current price of ₹970. They expect revenue growth to improve, driven by operational scale-up and upcoming empanelments, despite initial losses from the Noida facility. Overall, JM Financial anticipates a positive growth outlook for Medanta through FY28.

Business Standard

iShares Biotechnology ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Medanta valuation attractive post correction; JM Financial pegs 42% upside

Labcorp Holdings Inc. (LH) shares fell 2.78% to $262.91 on a poor trading day, while the S&P 500 and Dow Jones also declined. Despite this, Labcorp's performance was better than some competitors, with IQVIA down 5.04%, Centene down 3.60%, and Teladoc down 2.01%. Labcorp remains 10.49% below its 52-week high of $293.72 reached on October 21st. Trading volume was 734,820, surpassing the 50-day average of 715,209.

Dow Jones

Centene

IQVIA

Labcorp

Proshares Ultra Nasdaq Biotech

Labcorp Holdings Inc. Stock Outperforms Competitors Despite Losses On The Day

Teladoc Health shares are trading higher after Deutsche Bank upgraded the stock from Hold to Buy rating and announced a $11 price target.

Teladoc Health's stock surged after reporting better-than-expected quarterly results, with a loss of 14 cents per share against an anticipated 18 cents loss, and sales of $642.27 million exceeding expectations. However, the company provided cautious guidance for 2026, predicting a loss of 70 cents to $1.10 and sales between $2.47 billion and $2.59 billion. Analysts have mixed views, with Deutsche Bank upgrading the stock to Buy, while others like BTIG and Citigroup remain cautious, lowering price targets. Currently, TDOC is trading at $5.59, showing short-term strength but long-term struggles.

Teladoc Health Stock Pops - Here's Why

Deutsche Bank Aktiengesellschaft upgraded Teladoc Health (NYSE:TDOC) from a "hold" to a "buy" rating, setting a price target of $11.00, indicating a potential upside of 107.35%. Other analysts have varied opinions, with Oppenheimer lowering their target to $7.00 and Canaccord Genuity to $10.00. Currently, Teladoc has a consensus rating of "Hold" with a target of $7.76. The stock opened at $5.31, with a market cap of $946.41 million and a recent quarterly EPS of ($0.14), exceeding estimates. CEO Charles Divita III sold shares, reducing his stake by 7.86%.

Market Beat

Teladoc Health (NYSE:TDOC) Upgraded at Deutsche Bank Aktiengesellschaft

The global telehealth market is projected to exceed USD 2 trillion by 2034, driven by the rise in chronic diseases and the adoption of digital health technologies. Key factors include improved access to healthcare, government support, and the demand for convenient care. North America leads the market, followed by Europe and Asia-Pacific, with significant contributions from major companies like Teladoc and Siemens Healthineers. The market is expected to grow at a rate of approximately 32% from 2025 to 2032, reaching around USD 210 billion by 2025.

prnewswire

Siemens Healthineers AG

17:46 ETGlobal Telehealth Market is Projected to Cross the USD 2 Trillion Mark by 2034, Driven by Digital Healthcare Transformation | DelveInsight

Labcorp Holdings Inc. (LH) shares rose 1.46% to $273.61 on Monday, ending a five-day losing streak, while the S&P 500 and Dow Jones also gained. However, Labcorp's performance lagged behind competitors like IQVIA Holdings, which rose 2.33%, and Teladoc Health, which increased by 4.33%. Labcorp remains 6.85% below its 52-week high of $293.72 reached on October 21st, with trading volume at 563,045, below the 50-day average of 710,432.

Labcorp Holdings Inc. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains

ARVR

Teladoc Health Inc's short interest has increased by 9.38%, with 30.57 million shares sold short, representing 19.25% of available shares. It would take traders an average of 3.86 days to cover these positions. An increase in short interest indicates a bearish sentiment among investors. Compared to its peers, Teladoc's short interest is higher, with an average of 7.77% for similar companies. This data suggests that while short selling is on the rise, it does not necessarily predict a near-term decline in stock price.

First Trust Indxx Metaverse ETF

How Do Investors Really Feel About Teladoc Health Inc?

Global X Telemedicine & Digital Health ETF(EDOC.US)

Global X Telemedicine & Digital Health ETF Stock Performance Chart

Trending stocks this week as S&P 500 notches best weekly gain in 5 months

Teladoc Faces Pressure Over Capital Allocation And Stock Underperformance

SHL Telemedicine Narrows Loss and Bolsters Balance Sheet as Turnaround Advances

Teladoc Adds Susan Salka to Expanded Board of Directors

UberDoc Honored for Reverse Merger as Healthcare Marketplace Goes Public on CSE